U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Details

Stereochemistry ACHIRAL
Molecular Formula C8H15N7O2S3
Molecular Weight 337.445
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of FAMOTIDINE

SMILES

NC(=N)NC1=NC(CSCCC(=N)NS(N)(=O)=O)=CS1

InChI

InChIKey=XUFQPHANEAPEMJ-UHFFFAOYSA-N
InChI=1S/C8H15N7O2S3/c9-6(15-20(12,16)17)1-2-18-3-5-4-19-8(13-5)14-7(10)11/h4H,1-3H2,(H2,9,15)(H2,12,16,17)(H4,10,11,13,14)

HIDE SMILES / InChI

Description
Curator's Comment: Description was created based on several sources, including https://www.drugs.com/famotidine.html

Famotidine, a competitive histamine H2-receptor antagonist, is used to treat gastrointestinal disorders such as gastric or duodenal ulcer, gastroesophageal reflux disease, and pathological hypersecretory conditions. Famotidine inhibits many of the isoenzymes of the hepatic CYP450 enzyme system. Other actions of Famotidine include an increase in gastric bacterial flora such as nitrate-reducing organisms. Famotidine binds competitively to H2-receptors located on the basolateral membrane of the parietal cell, blocking histamine affects. This competitive inhibition results in reduced basal and nocturnal gastric acid secretion and a reduction in gastric volume, acidity, and amount of gastric acid released in response to stimuli including food, caffeine, insulin, betazole, or pentagastrin.

CNS Activity

CNS Penetrant
2588
Curator's Comment: Famotidine is a potent highly selective H2 receptor antagonist which crosses the blood-brain barrier.

Originator

Approval Year

1986
107
Targets

Targets

Primary TargetPharmacologyConditionPotency
Antagonist
2849
 0.3 µM [IC50]
Inhibitor
8504
 6.7 µM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Curative
Approved
8583
PEPCID

Approved Use

PEPCID is indicated in: 1. Short-term treatment of active duodenal ulcer. 2. Maintenance therapy for duodenal ulcer patients at reduced dosage after healing of an active ulcer. 3. Short-term treatment of active benign gastric ulcer. 4. Short-term treatment of gastroesophageal reflux disease (GERD). PEPCID is indicated for shortterm treatment of patients with symptoms of GERD PEPCID is also indicated for the short-term treatment of esophagitis due to GERD including erosive or ulcerative disease diagnosed by endoscopy 5. Treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison Syndrome, multiple endocrine adenomas)

Launch Date

1986
Curative
Approved
8583
PEPCID

Approved Use

PEPCID is indicated in: 1. Short-term treatment of active duodenal ulcer. 2. Maintenance therapy for duodenal ulcer patients at reduced dosage after healing of an active ulcer. 3. Short-term treatment of active benign gastric ulcer. 4. Short-term treatment of gastroesophageal reflux disease (GERD). PEPCID is indicated for shortterm treatment of patients with symptoms of GERD PEPCID is also indicated for the short-term treatment of esophagitis due to GERD including erosive or ulcerative disease diagnosed by endoscopy 5. Treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison Syndrome, multiple endocrine adenomas)

Launch Date

1986
Primary
Approved
8583
PEPCID

Approved Use

PEPCID is indicated in: 1. Short-term treatment of active duodenal ulcer. 2. Maintenance therapy for duodenal ulcer patients at reduced dosage after healing of an active ulcer. 3. Short-term treatment of active benign gastric ulcer. 4. Short-term treatment of gastroesophageal reflux disease (GERD). PEPCID is indicated for shortterm treatment of patients with symptoms of GERD PEPCID is also indicated for the short-term treatment of esophagitis due to GERD including erosive or ulcerative disease diagnosed by endoscopy 5. Treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison Syndrome, multiple endocrine adenomas)

Launch Date

1986
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
73 ng/mL
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/019462s039lbl.pdf
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
FAMOTIDINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
424 ng × h/mL
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/019462s039lbl.pdf
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
FAMOTIDINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
3 h
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/019462s039lbl.pdf
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
FAMOTIDINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
82.5%
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/019462s039lbl.pdf
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
FAMOTIDINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
0.5 mg/kg 2 times / day steady, oral
Recommended
Dose: 0.5 mg/kg, 2 times / day
Route: oral
Route: steady
Dose: 0.5 mg/kg, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/7846741/
unhealthy, 11 - 15 years
Health Status: unhealthy
Age Group: 11 - 15 years
Sex: M
Sources:
https://pubmed.ncbi.nlm.nih.gov/7846741/
Sources:
https://pubmed.ncbi.nlm.nih.gov/7846741/
80 mg 3 times / day steady, oral
Highest studied dose
Dose: 80 mg, 3 times / day
Route: oral
Route: steady
Dose: 80 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/32499303/
unhealthy, 20 - 70 years
Health Status: unhealthy
Age Group: 20 - 70 years
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/32499303/
Other AEs: Dizziness, Dry skin...
Other AEs:
Dizziness (grade 1, 2 patients)
Dry skin (grade 1, 1 patient)
Insomnia (grade 1, 1 patient)
Gastrointestinal disorder (NOS) (grade 1, 1 patient)
Forgetfulness (grade 1, 1 patient)
Sources:
https://pubmed.ncbi.nlm.nih.gov/32499303/
1 mg/kg 1 times / day steady, intravenous
Recommended
Dose: 1 mg/kg, 1 times / day
Route: intravenous
Route: steady
Dose: 1 mg/kg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/7846741/
unhealthy, 6 - 15 years
Health Status: unhealthy
Age Group: 6 - 15 years
Sex: M
Sources:
https://pubmed.ncbi.nlm.nih.gov/7846741/
Sources:
https://pubmed.ncbi.nlm.nih.gov/7846741/
26.6 mg 3 times / day steady, oral
Highest studied dose
Dose: 26.6 mg, 3 times / day
Route: oral
Route: steady
Dose: 26.6 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/23024710/
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/23024710/
Other AEs: Anemia, Nausea...
Other AEs:
Anemia (2 patients)
Nausea (6 patients)
Dyspepsia (5 patients)
Diarrhea (5 patients)
Constipation (4 patients)
Abdominal pain upper (3 patients)
Gastroesophageal reflux disease (2 patients)
Vomiting (2 patients)
Stomach discomfort (2 patients)
Abdominal pain (2 patients)
Edema peripheral (2 patients)
Arthralgia (1 patient)
Back pain (2 patients)
Headache (3 patients)
Hypertension (3 patients)
Sources:
https://pubmed.ncbi.nlm.nih.gov/23024710/
AEs

AEs

AESignificanceDosePopulation
Dry skin grade 1, 1 patient
80 mg 3 times / day steady, oral
Highest studied dose
Dose: 80 mg, 3 times / day
Route: oral
Route: steady
Dose: 80 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/32499303/
unhealthy, 20 - 70 years
Health Status: unhealthy
Age Group: 20 - 70 years
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/32499303/
Forgetfulness grade 1, 1 patient
80 mg 3 times / day steady, oral
Highest studied dose
Dose: 80 mg, 3 times / day
Route: oral
Route: steady
Dose: 80 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/32499303/
unhealthy, 20 - 70 years
Health Status: unhealthy
Age Group: 20 - 70 years
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/32499303/
Gastrointestinal disorder (NOS) grade 1, 1 patient
80 mg 3 times / day steady, oral
Highest studied dose
Dose: 80 mg, 3 times / day
Route: oral
Route: steady
Dose: 80 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/32499303/
unhealthy, 20 - 70 years
Health Status: unhealthy
Age Group: 20 - 70 years
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/32499303/
Insomnia grade 1, 1 patient
80 mg 3 times / day steady, oral
Highest studied dose
Dose: 80 mg, 3 times / day
Route: oral
Route: steady
Dose: 80 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/32499303/
unhealthy, 20 - 70 years
Health Status: unhealthy
Age Group: 20 - 70 years
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/32499303/
Dizziness grade 1, 2 patients
80 mg 3 times / day steady, oral
Highest studied dose
Dose: 80 mg, 3 times / day
Route: oral
Route: steady
Dose: 80 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/32499303/
unhealthy, 20 - 70 years
Health Status: unhealthy
Age Group: 20 - 70 years
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/32499303/
Arthralgia 1 patient
26.6 mg 3 times / day steady, oral
Highest studied dose
Dose: 26.6 mg, 3 times / day
Route: oral
Route: steady
Dose: 26.6 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/23024710/
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/23024710/
Abdominal pain 2 patients
26.6 mg 3 times / day steady, oral
Highest studied dose
Dose: 26.6 mg, 3 times / day
Route: oral
Route: steady
Dose: 26.6 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/23024710/
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/23024710/
Anemia 2 patients
26.6 mg 3 times / day steady, oral
Highest studied dose
Dose: 26.6 mg, 3 times / day
Route: oral
Route: steady
Dose: 26.6 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/23024710/
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/23024710/
Back pain 2 patients
26.6 mg 3 times / day steady, oral
Highest studied dose
Dose: 26.6 mg, 3 times / day
Route: oral
Route: steady
Dose: 26.6 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/23024710/
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/23024710/
Edema peripheral 2 patients
26.6 mg 3 times / day steady, oral
Highest studied dose
Dose: 26.6 mg, 3 times / day
Route: oral
Route: steady
Dose: 26.6 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/23024710/
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/23024710/
Gastroesophageal reflux disease 2 patients
26.6 mg 3 times / day steady, oral
Highest studied dose
Dose: 26.6 mg, 3 times / day
Route: oral
Route: steady
Dose: 26.6 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/23024710/
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/23024710/
Stomach discomfort 2 patients
26.6 mg 3 times / day steady, oral
Highest studied dose
Dose: 26.6 mg, 3 times / day
Route: oral
Route: steady
Dose: 26.6 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/23024710/
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/23024710/
Vomiting 2 patients
26.6 mg 3 times / day steady, oral
Highest studied dose
Dose: 26.6 mg, 3 times / day
Route: oral
Route: steady
Dose: 26.6 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/23024710/
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/23024710/
Abdominal pain upper 3 patients
26.6 mg 3 times / day steady, oral
Highest studied dose
Dose: 26.6 mg, 3 times / day
Route: oral
Route: steady
Dose: 26.6 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/23024710/
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/23024710/
Headache 3 patients
26.6 mg 3 times / day steady, oral
Highest studied dose
Dose: 26.6 mg, 3 times / day
Route: oral
Route: steady
Dose: 26.6 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/23024710/
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/23024710/
Hypertension 3 patients
26.6 mg 3 times / day steady, oral
Highest studied dose
Dose: 26.6 mg, 3 times / day
Route: oral
Route: steady
Dose: 26.6 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/23024710/
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/23024710/
Constipation 4 patients
26.6 mg 3 times / day steady, oral
Highest studied dose
Dose: 26.6 mg, 3 times / day
Route: oral
Route: steady
Dose: 26.6 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/23024710/
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/23024710/
Diarrhea 5 patients
26.6 mg 3 times / day steady, oral
Highest studied dose
Dose: 26.6 mg, 3 times / day
Route: oral
Route: steady
Dose: 26.6 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/23024710/
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/23024710/
Dyspepsia 5 patients
26.6 mg 3 times / day steady, oral
Highest studied dose
Dose: 26.6 mg, 3 times / day
Route: oral
Route: steady
Dose: 26.6 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/23024710/
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/23024710/
Nausea 6 patients
26.6 mg 3 times / day steady, oral
Highest studied dose
Dose: 26.6 mg, 3 times / day
Route: oral
Route: steady
Dose: 26.6 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/23024710/
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/23024710/
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG
inhibitor
2252
inhibitor
2217

OverviewOther

Other InhibitorOther SubstrateOther Inducer
CYP1A2
2153

CYP2B6
926

CYP2C19
2057

OCT1
620

OCT2
779

OCT3
159

MATE1
415

MATE2
267
OCT2
434
Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
CYP1A2
2333
 weak
likely (co-administration study)
Comment: may lead to substantial increases in blood concentrations of tizanidine, a CYP1A2 substrate; can't find inhibition value
Page: 6.0
OCT2
782
 yes [IC50 114 uM]
OCT1
656
 yes [IC50 28 uM]
OCT3
161
 yes [IC50 6.7 uM]
CYP2B6
1160
 yes [Inhibition 100 uM]
CYP2C19
2141
 yes [Inhibition 100 uM]
CYP3A4
2633
 yes [Inhibition 100 uM]
MATE1
416
 yes [Ki 0.6 uM]
MATE2
267
 yes [Ki 9.7 uM]
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
OCT2
434
 yes
Tox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
hERG
2263
Sourcing

Sourcing

Vendor/AggregatorIDURL
ChEBI
CHEBI:4975
https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:4975
ChemicalBook
CB5706585
https://www.chemicalbook.com/ChemicalProductProperty_EN_CB5706585
eMolecules
538460
https://www.emolecules.com/cgi-bin/more?vid=538460
eMolecules
6842898
https://www.emolecules.com/cgi-bin/more?vid=6842898
eMolecules
901873
https://www.emolecules.com/cgi-bin/more?vid=901873
MolPort
MolPort-002-557-620
https://www.molport.com/shop/molecule-link/MolPort-002-557-620
MolPort
MolPort-003-666-342
https://www.molport.com/shop/molecule-link/MolPort-003-666-342
MolPort
MolPort-003-941-395
https://www.molport.com/shop/molecule-link/MolPort-003-941-395
MolPort
MolPort-006-069-255
https://www.molport.com/shop/molecule-link/MolPort-006-069-255
Selleck Chemicals
famotidine-pepcid
http://www.selleckchem.com/products/famotidine-pepcid.html
ZINC
ZINC000001530636
http://zinc15.docking.org/substances/ZINC000001530636
PubMed

PubMed

TitleDatePubMed
Hemodynamic effects of quinidine and famotidine in patients with congestive heart failure.
1992 Mar
Prostacyclin analog prevents stress-induced expression of immediate early genes and gastric mucosal lesions in the rat stomach.
1999
[A case of rheumatoid arthritis associated with autoimmune hemolytic anemia due to weekly low-dose methotrexate therapy].
2000 Aug
Effect of polyunsaturated fatty acids on dexamethasone-induced gastric mucosal damage.
2000 Feb
Ultrasonographic evaluation of lansoprazole-induced improvement of submucosal injury in patients with gastroesophageal reflux.
2000 Feb
Developing a dynamic pharmacophore model for HIV-1 integrase.
2000 Jun 1
Delirium following a switch from cimetidine to famotidine.
2001 Sep
Effects of H(2)-receptor antagonists on dapsone-induced methaemoglobinaemia in rats.
2002 Apr
[A successfully treated case of intraoperative latex anaphylaxis during abdominal aorta aneurysm resection].
2003 Jan
Effect of exogenous administration of transforming growth factor-beta and famotidine on the healing of duodenal ulcer under the impact of indomethacin.
2003 Jun
On the mechanisms underlying histamine induction of gastric mucosal lesions in rats with partial gastric vascular occlusion.
2003 Jun
Famotidine for infant gastro-oesophageal reflux: a multi-centre, randomized, placebo-controlled, withdrawal trial.
2003 May 1
Different transport properties between famotidine and cimetidine by human renal organic ion transporters (SLC22A).
2004 Oct 25
Switching of H(2)-Receptor Antagonists to Over-the-Counter Status in Finland : Implications for Consumption and Adverse Effects.
2005
Comparison of an increased dosage regimen of rabeprazole versus a concomitant dosage regimen of famotidine with rabeprazole for nocturnal gastric acid inhibition in relation to cytochrome P450 2C19 genotypes.
2005 Apr
Effect of pre-operative short course famotidine on tumor infiltrating lymphocytes in colorectal cancer: a double blind, placebo controlled, prospective randomized study.
2005 Dec
Prediction of genotoxicity of chemical compounds by statistical learning methods.
2005 Jun
Randomized, double-blind, placebo-controlled crossover trial of famotidine in patients with functional dyspepsia.
2005 Jun
Alteration of intracellular histamine H2 receptor cycling precedes antagonist-induced upregulation.
2005 Nov
A species difference in the transport activities of H2 receptor antagonists by rat and human renal organic anion and cation transporters.
2005 Oct
Histamine mediates the stimulatory action of ghrelin on acid secretion in rat stomach.
2006 Aug
Cimetidine induces interleukin-18 production through H2-agonist activity in monocytes.
2006 Aug
In vitro availability of metformin in presence of h(2) receptor antagonists.
2006 Jan
Is the monkey an appropriate animal model to examine drug-drug interactions involving renal clearance? Effect of probenecid on the renal elimination of H2 receptor antagonists.
2006 Mar
Activity of continuous infusion plus pulse interleukin-2 with famotidine in patients with metastatic kidney cancer or melanoma previously treated with interleukin-2.
2006 Oct
Expression of HSP72 in the gastric mucosa is regulated by gastric acid in rats-correlation of HSP72 expression with mucosal protection.
2006 Oct 20
Impact of blockade of histamine H2 receptors on chronic heart failure revealed by retrospective and prospective randomized studies.
2006 Oct 3
Histamine stimulation of MMP-1(collagenase-1) secretion and gene expression in gastric epithelial cells: role of EGFR transactivation and the MAP kinase pathway.
2007
[Clinical study on effect of Jianwei Yuyang Granule in treating patients with gastric ulcer].
2007 Jul
Can negative cardiac effect of proton pump inhibitor and high-dose H2-blocker have clinical influence on patients with stable angina?
2008 Aug
Phosphodiesterase isozymes involved in regulating acid secretion in the isolated mouse stomach.
2009 Dec
Effects of pantoprazole on ulcer healing delay associated with NSAID treatment.
2009 Mar
Pulse infusion interleukin-2 with famotidine and cyclophosphamide has activity in previously treated metastatic melanoma.
2010 Apr
Rebamipide may be comparable to H2 receptor antagonist in healing iatrogenic gastric ulcers created by endoscopic mucosal resection: a prospective randomized pilot study.
2010 Apr
Effect of histamine H2 receptor antagonism on levodopa-induced dyskinesia in the MPTP-macaque model of Parkinson's disease.
2010 Jul 30
Hepatoprotective, antinociceptive and antioxidant activities of cimetidine, ranitidine and famotidine as histamine H2 receptor antagonists.
2011 Feb
Patents

Patents

05021582
2
JP2000197427A
2
JP2000219625A
2
JP2000302679A
2
JP2001302510A
2
JP2002017866A
2
JP2002087958A
2
JP2002145776A
2
JP2002291901A
2
JP2002322057A
2
JP2002511777A
420
JP2002537317A
97
JP2002538104A
9
JP2003088495A
2
JP2003095946A
2
JP2003206229A
2
JP2003212772A
2
JP2003261449A
2
JP2003275318A
2
JP2003275324A
2
JP2003275325A
2
JP2003284722A
2
JP2003305122A
2
JP2003515553A
3
JP2004223027A
2
JP2004261566A
2
JP2005168980A
2
JP2006089393A
2
JP2006273819A
2
JP2007008845A
5
JP2007055905A
2
JP2007284453A
2
JP2007507425A
18
JP2007518689A
11
JP2007525670A
150
JP2008504040A
2
JP2009526755A
475
JP2010088502A
2
JP2011079841A
5
JP2011223965A
2
JP2011229496A
2
JP2011525178A
25
JP2011528275A
456
JP4664289B2
2
JP4722295B2
105
JP4732696B2
68
JP4739217B2
51
JP4756823B2
22
JP4763957B2
87
JP4787165B2
104
JPH01100162A
2
JPH01197439A
2

Sample Use Guides

In Vivo Use Guide
The recommended adult oral dosage for active duodenal ulcer is 40 mg once a day at bedtime. Most patients heal within 4 weeks.
Route of Administration: Oral
In Vitro Use Guide
Famotidine (10-1,000 µM) inhibited methadone and oxycodone cytochrome P450-dependent metabolism >50%.
Name Type Language
FAMOTIDINE
EP   HSDB   INN   MART.   MI   ORANGE BOOK   USAN   USP   USP-RS   VANDF   WHO-DD  
INN   USAN  
Official Name English
PEPCID COMPLETE COMPONENT FAMOTIDINE
Preferred Name English
FLUXID
Brand Name English
GASTER
Brand Name English
MUCLOX
Brand Name English
AMFAMOX
Brand Name English
FAMOXAL
Brand Name English
PEPDUL
Brand Name English
Famotidine [WHO-DD]
Common Name English
[1-Amino-3-[[[2-[(diaminomethylene)amino]-4-thiazolyl]methyl]thio]propylidene]sulfamide
Systematic Name English
FAMOTIDINE [MART.]
Common Name English
PEPCIDINE
Brand Name English
FAMOTIDINE [JAN]
Common Name English
LECEDIL
Brand Name English
MOTIAX
Brand Name English
L 643341
Code English
GANOR
Brand Name English
FAMOTIDINE [MI]
Common Name English
famotidine [INN]
Common Name English
GASTRIDIN
Brand Name English
FAMODIL
Brand Name English
FAMOTIDINE [VANDF]
Common Name English
FAMOTIDINE [USP MONOGRAPH]
Common Name English
YM-11170
Code English
GASTROPEN
Brand Name English
PROPANIMIDAMIDE, N'-(AMINOSULFONYL)-3-(((2-((DIAMINOMETHYLENE)AMINO)-4-THIAZOLYL)METHYL)THIO)-
Systematic Name English
FAMOTIDINE [USP IMPURITY]
Common Name English
FAMOTIDINE [HSDB]
Common Name English
PEPCIDAC
Brand Name English
PEPDINE
Brand Name English
FADUL
Brand Name English
FAMOTIDINE [USP-RS]
Common Name English
FAMOTIDINE [USAN]
Common Name English
FAMOTIDINE [ORANGE BOOK]
Common Name English
FAMOSAN
Brand Name English
PEPCID
Brand Name English
FAMOTIDINE [EP MONOGRAPH]
Common Name English
NSC-757810
Code English
MK-208
Code English
3-((((2-(DIAMINOMETHYLENE)AMINO)-4-THIAZOLYL)METHYL)THIO)-N-SULFAMOYLPROPIONAMIDINE
Common Name English
Classification Tree Code System Code
WHO-ATC A02BA03
Created by admin on Mon Mar 31 18:11:48 GMT 2025 , Edited by admin on Mon Mar 31 18:11:48 GMT 2025
NDF-RT N0000175784
Created by admin on Mon Mar 31 18:11:48 GMT 2025 , Edited by admin on Mon Mar 31 18:11:48 GMT 2025
WHO-VATC QA02BA03
Created by admin on Mon Mar 31 18:11:48 GMT 2025 , Edited by admin on Mon Mar 31 18:11:48 GMT 2025
NCI_THESAURUS C29702
Created by admin on Mon Mar 31 18:11:48 GMT 2025 , Edited by admin on Mon Mar 31 18:11:48 GMT 2025
WHO-ATC A02BA53
Created by admin on Mon Mar 31 18:11:48 GMT 2025 , Edited by admin on Mon Mar 31 18:11:48 GMT 2025
LIVERTOX NBK548228
Created by admin on Mon Mar 31 18:11:48 GMT 2025 , Edited by admin on Mon Mar 31 18:11:48 GMT 2025
WHO-VATC QA02BA53
Created by admin on Mon Mar 31 18:11:48 GMT 2025 , Edited by admin on Mon Mar 31 18:11:48 GMT 2025
NDF-RT N0000000151
Created by admin on Mon Mar 31 18:11:48 GMT 2025 , Edited by admin on Mon Mar 31 18:11:48 GMT 2025
Code System Code Type Description
LACTMED
Famotidine
Created by admin on Mon Mar 31 18:11:48 GMT 2025 , Edited by admin on Mon Mar 31 18:11:48 GMT 2025
PRIMARY
EPA CompTox
DTXSID5023039
Created by admin on Mon Mar 31 18:11:48 GMT 2025 , Edited by admin on Mon Mar 31 18:11:48 GMT 2025
PRIMARY
DRUG BANK
DB00927
Created by admin on Mon Mar 31 18:11:48 GMT 2025 , Edited by admin on Mon Mar 31 18:11:48 GMT 2025
PRIMARY
NSC
757810
Created by admin on Mon Mar 31 18:11:48 GMT 2025 , Edited by admin on Mon Mar 31 18:11:48 GMT 2025
PRIMARY
MESH
D015738
Created by admin on Mon Mar 31 18:11:48 GMT 2025 , Edited by admin on Mon Mar 31 18:11:48 GMT 2025
PRIMARY
EVMPD
SUB07503MIG
Created by admin on Mon Mar 31 18:11:48 GMT 2025 , Edited by admin on Mon Mar 31 18:11:48 GMT 2025
PRIMARY
DAILYMED
5QZO15J2Z8
Created by admin on Mon Mar 31 18:11:48 GMT 2025 , Edited by admin on Mon Mar 31 18:11:48 GMT 2025
PRIMARY
INN
5217
Created by admin on Mon Mar 31 18:11:48 GMT 2025 , Edited by admin on Mon Mar 31 18:11:48 GMT 2025
PRIMARY
SMS_ID
100000092363
Created by admin on Mon Mar 31 18:11:48 GMT 2025 , Edited by admin on Mon Mar 31 18:11:48 GMT 2025
PRIMARY
IUPHAR
7074
Created by admin on Mon Mar 31 18:11:48 GMT 2025 , Edited by admin on Mon Mar 31 18:11:48 GMT 2025
PRIMARY
PUBCHEM
3325
Created by admin on Mon Mar 31 18:11:48 GMT 2025 , Edited by admin on Mon Mar 31 18:11:48 GMT 2025
PRIMARY
MERCK INDEX
m5241
Created by admin on Mon Mar 31 18:11:48 GMT 2025 , Edited by admin on Mon Mar 31 18:11:48 GMT 2025
PRIMARY Merck Index
ChEMBL
CHEMBL902
Created by admin on Mon Mar 31 18:11:48 GMT 2025 , Edited by admin on Mon Mar 31 18:11:48 GMT 2025
PRIMARY
RXCUI
4278
Created by admin on Mon Mar 31 18:11:48 GMT 2025 , Edited by admin on Mon Mar 31 18:11:48 GMT 2025
PRIMARY RxNorm
WIKIPEDIA
FAMOTIDINE
Created by admin on Mon Mar 31 18:11:48 GMT 2025 , Edited by admin on Mon Mar 31 18:11:48 GMT 2025
PRIMARY
RS_ITEM_NUM
1269200
Created by admin on Mon Mar 31 18:11:48 GMT 2025 , Edited by admin on Mon Mar 31 18:11:48 GMT 2025
PRIMARY
CHEBI
4975
Created by admin on Mon Mar 31 18:11:48 GMT 2025 , Edited by admin on Mon Mar 31 18:11:48 GMT 2025
PRIMARY
DRUG CENTRAL
1129
Created by admin on Mon Mar 31 18:11:48 GMT 2025 , Edited by admin on Mon Mar 31 18:11:48 GMT 2025
PRIMARY
USAN
W-33
Created by admin on Mon Mar 31 18:11:48 GMT 2025 , Edited by admin on Mon Mar 31 18:11:48 GMT 2025
PRIMARY
HSDB
3572
Created by admin on Mon Mar 31 18:11:48 GMT 2025 , Edited by admin on Mon Mar 31 18:11:48 GMT 2025
PRIMARY
NCI_THESAURUS
C29045
Created by admin on Mon Mar 31 18:11:48 GMT 2025 , Edited by admin on Mon Mar 31 18:11:48 GMT 2025
PRIMARY
FDA UNII
5QZO15J2Z8
Created by admin on Mon Mar 31 18:11:48 GMT 2025 , Edited by admin on Mon Mar 31 18:11:48 GMT 2025
PRIMARY
CAS
76824-35-6
Created by admin on Mon Mar 31 18:11:48 GMT 2025 , Edited by admin on Mon Mar 31 18:11:48 GMT 2025
PRIMARY
ACTIVE MOIETY
Structure of FAMOTIDINE
METABOLITE (PARENT)
Structure of FAMOTIDINE SULFOXIDE
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966